Compare TransMedics Group Inc (TMDX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Western Alliance Bancorporation — how do they compare? TransMedics Group Inc trades at $80.83 (market cap $2.74B), while Western Alliance Bancorporation trades at $74.72 (market cap $8.24B). The key difference: Western Alliance Bancorporation is far larger — about 3× TransMedics Group Inc's market cap, and Western Alliance Bancorporation pays a 2.23% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Western Alliance Bancorporation for 3 Days on average.
| TMDX | WAL | |
|---|---|---|
Market Cap | $2.74B | $8.24B |
Volume | 949,331 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $150.42 | $96.08 |
52-Week Low | $61.99 | $66.70 |
Typical Hold Time | 24 Days | 3 Days |
Enterprise Value | $3.13B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% today, with a bearish technical signal but strong fundamentals including a P/E of 8.52 and net income margin of 25.43%. Recent Q2 2026 earnings missed EPS estimates at $2.36, though revenue and profitability trends remain positive. The company launched WA VenueX, an institutional financial platform, and announced a $0.42 dividend for H2-2026.
Outlook is mixed: analyst consensus is strongly bullish with a $84.33 price target, but technical indicators signal near-term pressure. Key risks include interest rate sensitivity and regulatory changes, while institutional buying and solid valuation metrics support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
